Weekly briefings only appear here after editorial review and public publish. Until the next edition clears, use the archive for recent GLP-1 signal or start with the current patient guides below.
GLP-1 medications like semaglutide and tirzepatide help women with PCOS who have obesity or insulin resistance by promoting weight loss and improving metabolic health, though their direct impact on hormonal and reproductive symptoms remains unclear and varies by individual.
Read moreWegovy is a once-weekly injection for weight management with a stepwise dose escalation from 0.25 mg to 2.4 mg over about 16 weeks to improve tolerance and minimize side effects. A higher 7.2 mg dose was FDA-approved in early 2026 but is not yet widely available. Proper injection technique, missed dose management, and ongoing clinician supervision are essential.
Read moreA plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreAcross GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisGLP-1 medications like semaglutide and tirzepatide help women with PCOS who have obesity or insulin resistance by promoting weight loss and improving metabolic health, though their direct impact on hormonal and reproductive symptoms remains unclear and varies by individual.
Full analysisWe track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Started publishing Jan 2020
Rami Bailony writes from inside obesity medicine, and that makes the coverage more useful than the publication’s size might suggest. The pieces stay close to treatment design, patient experience, and the difference between meaningful obesity care and generic weight-loss messaging. It is a smaller desk, but a very on-topic one for readers who want specialist perspective with real operating context.
Started publishing Jan 2023
Ragen Chastain’s newsletter is a deliberate counterweight to mainstream obesity and GLP-1 coverage. Readers will find skepticism, anti-stigma arguments, and a very different read on weight-centric care than they get from most medical or business publications. You may not agree with every conclusion, but it is a useful source when you want to test the assumptions driving the rest of the category.
Started publishing Jan 2022
Mara Gordon’s writing is useful if you want a more humane and less weight-fixated way of thinking about care. The newsletter is strongest when it pushes back on stigma, over-simplified weight talk, and the idea that obesity care should be reduced to a single number on the scale. It is a strong read for anyone who wants the patient-trust side of this category, not just the product side.
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.